e-learning
resources
ERJ
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Efficacy and safety of inhaled a1-antitrypsin in patients with severe a1-antitrypsin deficiency and frequent exacerbations of COPD
Jan Stolk, Naveh Tov, Kenneth R. Chapman, Pablo Fernandez, William MacNee, Nicholas S. Hopkinson, Eeva Piitulainen, Niels Seersholm, Claus F. Vogelmeier, Robert Bals, Gerry McElvaney, Robert A. Stockley
Source:
Eur Respir J, 54 (5) 1900673; 10.1183/13993003.00673-2019
Journal Issue:
November
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Jan Stolk, Naveh Tov, Kenneth R. Chapman, Pablo Fernandez, William MacNee, Nicholas S. Hopkinson, Eeva Piitulainen, Niels Seersholm, Claus F. Vogelmeier, Robert Bals, Gerry McElvaney, Robert A. Stockley. Efficacy and safety of inhaled a1-antitrypsin in patients with severe a1-antitrypsin deficiency and frequent exacerbations of COPD. Eur Respir J, 54 (5) 1900673; 10.1183/13993003.00673-2019
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
Evidence-based eHealth for COPD
Related content which might interest you:
Long-term effect of roflumilast on exacerbations in patients with severe to very severe COPD
Source: Eur Respir J 2006; 28: Suppl. 50, 526s
Year: 2006
Evaluating the efficacy of omalizumab in severe persistent asthma patients
Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies
Year: 2017
Efficacy and safety of intravenous montelukast in patients with acute exacerbations of bronchial asthma
Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of asthma
Year: 2008
Roflumilast added to triple therapy in severe COPD patients with frequent exacerbations: Efficacy and tolerability
Source: International Congress 2014 – Markers
Year: 2014
Exacerbations of severe asthma in patients treated with mepolizumab
Source: Eur Respir J, 52 (6) 1801127; 10.1183/13993003.01127-2018
Year: 2018
Ceruloplasmine efficacy in patients with asthma exacerbations
Source: Annual Congress 2011 - Novel mechanisms in lung injury
Year: 2011
Impact of omalizumab in patients with severe asthma
Source: Annual Congress 2009 - Aspects of uncontrolled asthma
Year: 2009
Triple therapy for all patients with severe symptomatic COPD at risk of exacerbations
Source: Eur Respir J, 53 (4) 1900147; 10.1183/13993003.00147-2019
Year: 2019
Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results
Source: Eur Respir J 2009; 34: 641
Year: 2009
Efficacy of roflumilast in the frequent exacerbation COPD phenotype
Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD
Year: 2011
Add-on omalizumab therapy reduces clinically significant and severe asthma exacerbations, and improves FEV
1
in patients with severe persistent allergic asthma irrespective of age
Source: Eur Respir J 2005; 26: Suppl. 49, 48s
Year: 2005
Clinical effectiveness of nebulized budesonide in the treatment of acute asthma and exacerbations of chronic obstructive pulmonary disease (COPD)
Source: Eur Respir J 2001; 18: Suppl. 33, 146s
Year: 2001
Severe outcomes of COVID-19 among patients with COPD and asthma
Source: ERJ Open Res, 7 (1) 00594-2020; 10.1183/23120541.00594-2020
Year: 2021
Oral montelukast in patients with acute severe asthma
Source: Annual Congress 2007 - Recent advances in our understanding of the treatment of asthma
Year: 2007
The efficacy and safety of inhaled fluimucil-antibiotic-IT in the treatment of exacerbations of COPD and chronic bronchitis with bronchiectasis
Source: Annual Congress 2013 –COPD diagnosis
Year: 2013
Effect of dupilumab on severe exacerbations in asthma patients with and without lung function improvements
Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma
Year: 2020
Inhaled corticosteroids and the risk of a first exacerbation in COPD patients
Source: Eur Respir J 2004; 23: 692-697
Year: 2004
Impact of moderate and severe exacerbations in severe COPD patients
Source: International Congress 2018 – How far are we in terms of predicting mortality and exacerbations in COPD?
Year: 2018
Montelukast as add-on therapy in severe noninfectious COPD exacerbations
Source: Eur Respir J 2003; 22: Suppl. 45, 241s
Year: 2003
Inhaled corticosteroid use is associated with lower mortality for subjects with COPD and hospitalised with pneumonia
Source: Eur Respir J 2010; 36: 751-757
Year: 2010
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept